- Home
- PRLD vs MCHX Comparison
PRLD vs MCHX Comparison
Compare PRLD & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | MCHX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 71.6M |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | PRLD | MCHX |
|---|---|---|
| Price | $2.78 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 534.1K | 22.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,500,000.00 | ★ $46,494,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $1.26 |
| 52 Week High | $4.22 | $2.31 |
Technical Indicators
Market Signals| Indicator | PRLD | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 58.45 |
| Support Level | $2.37 | $1.59 |
| Resistance Level | $3.00 | $1.69 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 78.39 | 85.05 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About MCHX Marchex Inc. Class B
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.